The internal research team revealed the mechanism of promoting osteosarcoma progression, a rare incurable cancer, and established a key to the development of treatment methods.
Dr. Park Jong-gue of the Department of Clinical Medicine, the National Cancer Center, Dr. Yong-Yon Kim of the Pediatric Transplantation Department, and Professor Sun Ji-Muun of the Department of Cancer Research, Department of Cancer, that they have found that specific protein promotes osteosarcoma by promoting osteosarcoma. The osteosarcoma that appears in the bone is considered a poor prognosis because it is often metastatic and resistant to anticancer drugs.
The researchers have found that a protein called ICSBP (Interferon Consensus Sequence-Binding Protein) promotes transforming growth factor signal transduction (TGF-β, TGF-β) and thus acquires the characteristics of proliferation and metastasis of osteosarcoma cells.
The "TGF-β" protein is a typical growth factor involved in various physiological processes of the body that typically inhibits the proliferation of cancer cells.
In particular, they also confirmed that ICSBP promotes signal transduction by activating a capture engine by binding to a specific position of the promoter type 1 (TGF-pRI) transforming growth factor. In addition, animal studies in animals have shown that inhibition of ICSBP expression in osteosarcoma cells results in reduced expression of TGF-pRI and inhibition of osteosarcoma growth.
"We expect the results of this study to provide new guidelines for the development of osteosarcoma treatment by revealing the progressive mechanism of osteosarcoma, which is a rare disease." The results of the study are published in the current issue of the International Journal of Biochimica et Biophysica Acta (BBA, Molecular Cell Study).[이병문 의료전문 기자][ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지]